4565   Sosei Group Corporation

06/27/2024 08:00	Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
05/30/2024 15:30	Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
05/09/2024 15:30	Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
05/09/2024 15:30	Consolidated Financial Results for the Three months Ended March 31, 2024 (IFRS)
04/16/2024 15:30	Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
04/15/2024 08:30	Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ in South Korea
03/27/2024 15:30	Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma
03/21/2024 08:30	Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease (IBD)
03/11/2024 15:30	Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia
03/06/2024 15:30	Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals
02/29/2024 08:00	Notice of 2024 Annual General Meeting and Meeting Materials
02/16/2024 08:30	Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office
02/13/2024 15:30	Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023
02/13/2024 15:30	Consolidated Financial Results for the FY2023 (IFRS)
12/07/2023 15:30	Sosei Group Announces Marketing Approval for PIVLAZ (clazosentan sodium) 150 mg in South Korea
11/29/2023 01:40	Sosei Heptares Announces Determination of the Issuance Terms for its New Shares, Convertible Bonds and Third Party Allotment
11/28/2023 16:20	Sosei Heptares Announces Issuance of New Shares and Convertible Bonds and Buyback of Existing Convertible Bonds
11/10/2023 15:30	Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023
11/10/2023 15:30	Consolidated Financial Results for the Nine Months Ended September 30, 2023 (IFRS)
10/31/2023 15:30	Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership
10/31/2023 15:30	Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
08/10/2023 15:30	Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase 1/2a Trial with Cancer Immunotherapy Drug HTL0039732
08/04/2023 15:30	Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
08/04/2023 15:30	Consolidated Financial Results for the Six Months Ended June 30, 2023 (IFRS)